Table 1.
Characteristics of the patients cohort and target lesions.
| Characteristic | Value |
|---|---|
| Age [yr] | 71 (55–84) |
| PSA at baseline [ng/mL], median (minimum–maximum) | 469 (0.08–2907) |
| ECOG performance status category at baseline, % (n) | |
| 0 | 14% (3) |
| 1 | 45% (10) |
| ≥ 2 | 41% (9) |
| Prior treatment, % [no.] | |
| Prostatectomy | 55% (12) |
| Radiation therapy | 64% (14) |
| ADT | 100% (22) |
| NAAD | 100% (22) |
| Chemotherapy | |
| Any | 77% (17) |
| Docetaxel | 77% (17) |
| Cabazitaxel | 45% (10) |
| Other | 14% (3) |
| Radium-223 | 14% (3) |
| [177Lu]Lu-PSMA-617 RLT activities [GBq], median (minimum–maximum) | |
| First activity | 8.6 (1.1–10.6) |
| Second activity | 8.2 (1.5–9.3) |
| Cumulative activity | 16.7 (2.6–19.4) |
| Target lesions category, n (%) | |
| Any | 267 (100%) |
| Lymph node | 49 (18.4%) |
| Bone | 212 (79.4%) |
| Liver | 6 (2.2%) |
| Number per patient | |
| Mean ± SD | 12 ± 4 |
| Median (minimum–maximum) | 14 (1–14) |
ADT androgen deprivation therapy, ECOG eastern cooperative oncology group, NAAD novel androgen access drugs, PSA, prostate-specific antigen.